AK
AKP.F Anika Therapeutics Inc
- Market cap
- EUR 165M
- P/E
- -
- P/B
- 1.38x
- ROE
- -2.0%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is AKP.F undervalued?
Graham numberThe Graham number of Anika Therapeutics Inc cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Anika Therapeutics Inc fundamental analysis
No fundamental analysis for Anika Therapeutics Inc yet.
Anika Therapeutics Inc stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Anika Therapeutics Inc
Anika Therapeutics, Inc., a joint preservation company, focuses on early intervention orthopedics in the United States, Europe, and internationally. The company offers osteoarthritis (OA) pain management products and services, such as Monovisc and Orthovisc, which are single- and multi-injection, HA viscosupplement products indicated for pain relief from OA conditions, as well as Cingal, a non-opioid, single-injection OA pain management product; regenerative solutions, inclu…
Full company profileAnika Therapeutics Inc financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Anika Therapeutics Inc annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 103M | 113M | 106M | 115M | 130M | 148M | 156M | 121M | 120M | 113M | 124M |
| Gross Profit | 79.4M | 86.1M | 74.3M | 85.9M | 69.0M | 82.9M | 93.6M | 82.5M | 76.0M | 63.8M | 78.8M |
| Operating Income | 50.6M | 45.7M | 21.7M | 34.2M | -14.5M | -18.5M | -19.4M | 844K | -5.10M | -11.1M | -4.33M |
| EBITDA | - | 50.0M | 27.7M | 40.2M | -1.00M | -4.16M | 18.2M | 15.1M | 3.02M | -5.32M | 1.47M |
| Net Income | 32.5M | 31.8M | 18.7M | 27.2M | -24.0M | 4.13M | -14.9M | -82.7M | -56.4M | -10.9M | -2.74M |
| EPS | - | 2.17 | 1.32 | 1.90 | -1.67 | 0.29 | -1.02 | -5.64 | -3.91 | -0.78 | -0.20 |
| Balance Sheet | |||||||||||
| Total Assets | 240M | 283M | 279M | 331M | 366M | 348M | 349M | 271M | 203M | 190M | 190M |
| Total Liabilities | 17.5M | 19.1M | 15.4M | 42.3M | 93.2M | 60.5M | 63.6M | 58.4M | 48.8M | 46.8M | 52.0M |
| Shareholders' Equity | 223M | 263M | 264M | 288M | 272M | 287M | 286M | 212M | 154M | 143M | 138M |
| Cash & Short-term Investments | 104M | 133M | 89.0M | 157M | 95.8M | 94.4M | 86.3M | 72.9M | 55.6M | 57.5M | 45.0M |
| Cash Flow | |||||||||||
| Operating Cash Flow | 24.4M | 40.8M | 34.9M | 37.0M | 13.1M | 8.40M | 4.41M | -1.79M | 5.40M | 11.2M | 3.80M |
| Capital Expenditure | 14.0M | 8.98M | 4.66M | 2.83M | 1.63M | 5.14M | 7.49M | 5.43M | 8.33M | 6.83M | 6.05M |
| Free Cash Flow | - | 31.8M | 30.3M | 34.2M | 11.4M | 3.25M | -3.08M | -7.22M | -2.93M | 4.36M | -2.26M |
| Ratios | |||||||||||
| ROE | 14.6% | 12.1% | 7.1% | 9.4% | -8.8% | 1.4% | -5.2% | -38.9% | -36.6% | -7.6% | -2.0% |
| ROA | 13.5% | 11.3% | 6.7% | 8.2% | -6.6% | 1.2% | -4.3% | -30.5% | -27.8% | -5.7% | -1.4% |
| Net Profit Margin | 31.5% | 28.1% | 17.7% | 23.7% | -18.4% | 2.8% | -9.5% | -68.4% | -47.0% | -9.6% | -2.2% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
Anika Therapeutics Inc dividends
Anika Therapeutics Inc has not paid dividends in the last 9 fiscal years.
Who owns Anika Therapeutics Inc
- Insiders 6.40%
- Institutions 93.60%
- Public & others 0.00%
- Shares outstanding 13.4M
- Free float 11.3M
Anika Therapeutics Inc company profile
- Company name
- Anika Therapeutics Inc
- Ticker
- AKP.F
- Exchange
- Frankfurt Exchange
- Sector
- Healthcare
- Industry
- Health Care Equipment & Supplies
- Employees
- 235
- Fiscal year end
- December
- Address
- 32 Wiggins Avenue, Bedford, MA, United States, 01730
- Phone
- 781 457 9000
- Website
- anika.com
About Anika Therapeutics Inc
Anika Therapeutics, Inc., a joint preservation company, focuses on early intervention orthopedics in the United States, Europe, and internationally. The company offers osteoarthritis (OA) pain management products and services, such as Monovisc and Orthovisc, which are single- and multi-injection, HA viscosupplement products indicated for pain relief from OA conditions, as well as Cingal, a non-opioid, single-injection OA pain management product; regenerative solutions, including an HA-based scaffold with bone and tendon fixation components and arthroscopic delivery instruments; Hyalofast, a resorbable scaffold used for single stage cartilage regeneration; and Tactoset injectable bone substitute, an HA-enhanced injectable bone repair therapy designed to treat insufficiency fractures and augment hardware fixation. It also provides Integrity, an HA-based scaffold with bone and tendon fixation components and arthroscopic delivery instruments; non-orthopedic products, including Hyvisc, a high molecular weight injectable HA veterinary product for the treatment of joint dysfunction in horses due to non-infectious synovitis associated with equine OA; Hyalobarrier, an anti-adhesion barrier indicated for use after abdominal-pelvic surgeries; and ophthalmic products; and Anikavisc and Nuvisc high molecular weight HA products. The company was founded in 1983 and is headquartered in Bedford, Massachusetts.
Anika Therapeutics Inc management
7- Dr. Cheryl Renee Blanchard Ph.D.Executive Chair · born 1964
- Mr. Stephen D. GriffinPresident, Principal Financial Officer, CEO & Director · born 1986
- Mr. Ian W. McLeodSenior VP, Chief Accounting Officer & Treasurer · born 1966
- Mr. Matthew HallExecutive Director of Corporate Development & Investor Relations
- Ms. Lisa FunicielloVP & Chief Human Resources Officer
- Mr. Ben JosephSenior Vice President of Commercial
- Ms. Mira LeiwantSenior Vice President of Regulatory, Quality & Clinical Affairs